SWALLOWTAIL and LONGWING Open-label Extension Studies for Children and Adolescents with Dravet Syndrome who Previously Participated in a Study of Antisense Oligonucleotide Zorevunersen (STK-001)

Topic: Genetic Epilepsies Presentations

SWALLOWTAIL and LONGWING Open-label Extension Studies for Children and Adolescents with Dravet Syndrome who Previously Participated in a Study of Antisense Oligonucleotide Zorevunersen (STK-001)

EEC 2024

September 10, 2024

View Poster

MONARCH and ADMIRAL: Open-label, Phase 1/2a studies in USA and UK investigating safety, drug exposure, and clinical effect of zorevunersen(STK-001), an antisense oligonucleotide, in children and adolescents with Dravet syndrome

EEC 2024

September 10, 2024

View Presentation

24-Month Analysis of BUTTERFLY A Prospective, Observational Study to Investigate Seizures and Comorbidities in Children and Adolescents with Dravet Syndrome

EEC 2024

September 10, 2024

View Poster

Utilization of a Pharmacokinetic (PK) Model for STK-001 in Patients with Dravet Syndrome (DS) To Support Selection of Dosing Regimens in Clinic

AES 2023

December 1, 2023

View Poster